Publication:
In silico development of dna aptamer-targeting breast cancer soluble pdl-1 (spdl-1) protein

dc.contributor.authorYazid, Ahmad Arif Akmal
dc.date.accessioned2026-08-23T08:24:54Z
dc.date.available2026-08-23T08:24:54Z
dc.date.issued2026-01
dc.description.abstractThis study aimed to develop an aptamer-based bioassay, also known as enzyme-linked oligonucleotide assay (ELONA), for the detection of soluble programmed death-ligand 1 (sPD-L1) by integrating in-silico approaches with experimental validation. sPD-L1 is an important immune-related cancer biomarker; however, conventional antibody-based ELISA methods are limited by high cost, stability issues and batch-to-batch variability. In this work, multiple ssDNA aptamers were generated and systematically screened in- silico using secondary and three-dimensional structure prediction, molecular docking, protein–ligand interaction analysis and molecular dynamics simulations to identify a candidate with favourable binding affinity and complex stability toward PD-L1. The selected aptamer was subsequently validated experimentally using ELONA. The assay demonstrated concentration-dependent and saturable binding of the aptamer to immobilised PD-L1, with a moderate equilibrium dissociation constant (Kd), indicating functional and specific interaction. Overall, the findings confirm the feasibility of combining in-silico guided aptamer selection with experimental ELONA development and support the potential of aptamers as viable alternatives to antibodies in cancer biomarker detection.
dc.identifier.urihttps://erepo.usm.my/handle/123456789/24887
dc.language.isoen
dc.titleIn silico development of dna aptamer-targeting breast cancer soluble pdl-1 (spdl-1) protein
dc.typeResource Types::text::thesis::bachelor thesis
dspace.entity.typePublication
oairecerif.author.affiliationUniversiti Sains Malaysia
Files